Chimeric antigen receptors with mutated CD28 phosphorylation sites
US12077598B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Mar 15, 2019 |
| Grant date | Sep 3, 2024 |
| Priority date | — |
| Expiry date | Nov 13, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/33
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed herein are chimeric antigen receptor (CAR) polypeptides, which can be used with adoptive cell transfer to target and kill cancers, that comprise a costimulatory signaling region having a mutated form of a cytoplasmic domain of CD28 with altered phosphorylation at Y206 and/or Y218. Also disclosed are immune effector cells, such as T cells or Natural Killer (NK) cells, that are engineered to express these CARs. Therefore, also disclosed are methods of providing an antitumor immunity in a subject with a tumor associated antigen-expressing cancer that involves adoptive transfer of the disclosed immune effector cells engineered to express the disclosed CARs.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.